Apriso Oral Capsule, Biphasic Release 0.375G Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Apriso: Oral capsule, biphasic release (0.375g)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_13859.JPG
Apriso 0.375g ER Cap
Salix Pharmaceuticals, Inc
Pill Identification: G M 

What is this Medicine?

MESALAMINE (me SAL a meen) is used to maintain remission of ulcerative colitis.

CVS Pharmacy Patient Statistics for Apriso: Oral capsule, biphasic release(0.375g)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Apriso 0.375g Extended-Release Capsule

NDC: 656490103
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved





Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Apriso 0.375g Extended-Release Capsule
Drug Image file DrugItem_13859.JPG
Salix Pharmaceuticals, Inc
Pill Identification: G M 
Shape: capsule
Color: blue

Reported Side Effects for Apriso 0.375g Extended-Release Capsule

Hives Incidence:
<3.0%*
Severity: MILD
Onset: RAPID
Inflamed Pancreas Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Diaphoresis Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Feeling Sick Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Rapid Heart Rate Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Rapid Heart Rate Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Upset Stomach Incidence:
<6.0%*
Severity: MILD
Onset: EARLY
Acne Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Hair Loss Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Anemia Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
High Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Low Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Itching Incidence:
<3.0%*
Severity: MILD
Onset: RAPID
Muscle Pain Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
1.0-11.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
2.0-15.0%*
Severity: MILD
Onset: EARLY
Migraine Incidence:
>2.0%*
Severity: MODERATE
Onset: EARLY
Tenesmus Incidence:
>2.0%*
Severity: MILD
Onset: DELAYED
Intestinal Bleeding Incidence:
>2.0%*
Severity: SEVERE
Onset: DELAYED
Stomach Pain Incidence:
2.0-21.0%*
Severity: MILD
Onset: EARLY
Hemorrhoids Incidence:
>2.0%*
Severity: MODERATE
Onset: DELAYED
Peripheral Vasodilation Incidence:
>2.0%*
Severity: MODERATE
Onset: RAPID
Paresthesias Incidence:
>2.0%*
Severity: MILD
Onset: DELAYED
Inflamed Colon Incidence:
3.0-12.0%*
Severity: MODERATE
Onset: DELAYED
Flu Incidence:
>4.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
4.0%*
Severity: MILD
Onset: EARLY
Gas Incidence:
4.0-6.1%*
Severity: MILD
Onset: EARLY
Headache Incidence:
5.0-53.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
>5.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
5.0-6.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Rhinitis Incidence:
>5.0%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
>5.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
>5.0%*
Severity: MILD
Onset: EARLY
Belching Incidence:
16.0-26.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Apriso

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5